X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The study met all primary and secondary endpoints, with all results indicating that the inhalation of APN01 (alunacedase alfa) at all dosage levels used in the trial is safe and well tolerated.
Lead Product(s): Alunacedase Alfa
Therapeutic Area: Infections and Infectious Diseases Product Name: APN01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
Primary study objective is the evaluation of safety and tolerability of single ascending doses (SADs) and multiple ascending doses (MADs) of inhaled APN01 when administered via a jet nebulizer in healthy subjects.
Lead Product(s): Alunacedase Alfa
Therapeutic Area: Infections and Infectious Diseases Product Name: APN01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
Under the Subscription Agreement dated 2 June 2020 with Apeiron, Apeiron agreed to recapitalise the Company and assist in securing further equity capital to fund the Company's BNC210 Phase 2b Clinical trial for the treatment of post-traumatic stress disorder.
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Bionomics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing February 10, 2021
Details:
Sensei’s lead ImmunoPhage product candidate, SNS301, is being evaluated in a Phase 1/2 trial for the treatment of locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab.
Lead Product(s): SNS-301,Pembrolizumab
Therapeutic Area: Oncology Product Name: SNS-301
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: Sensei Biotherapeutics
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 11, 2021
Details:
Domainex will provide its expertise in medicinal and computational chemistry, screening, structural biology and ADME/PK to advance APEIRON’s promising Cbl-b targeting compound series APN431 towards pre-clinical development.
Lead Product(s): APN431
Therapeutic Area: Oncology Product Name: APN431
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Domainex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 09, 2020
Details:
Case study from promising first COVID-19 patient treatment with APN01 supports APEIRON’s ongoing pivotal Phase II clinical trial.
Lead Product(s): Alunacedase alfa
Therapeutic Area: Infections and Infectious Diseases Product Name: APN01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2020
Details:
Under the terms of this licensing agreement, APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials.
Lead Product(s): APN401
Therapeutic Area: Oncology Product Name: APN401
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: MaxCyte
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 07, 2020
Details:
Regulatory approvals obtained for the treatment of 200 COVID-19 patients in Austria, Germany and Denmark; Austrian government to provide significant financial support.
Lead Product(s): APN01
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
Details:
The randomized, unblinded trial will treat 24 patients for seven days to obtain preliminary data on the impact of rhACE2 on biological, physiologic, and clinical outcomes and safety in patients.
Lead Product(s): APN01
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
